# Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)

Study · id `cardio:ct-nct02666664` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02666664](<https://clinicaltrials.gov/study/NCT02666664>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02666664

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2230 participants.

## Technical summary

Registry record NCT02666664. Randomized; triple masking; primary purpose treatment. Start 2016-01-21 (actual); primary completion 2018-02-21 (actual). Results posted on 2020-04-20.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 2230 participants (enrolled count; ClinicalTrials.gov record NCT02666664, source copy `cardio:ctgov-nct02666664-2020-05-11`, retrieved 2026-10-31)
- Started: 2016-01-21 (actual) (ClinicalTrials.gov record NCT02666664, source copy `cardio:ctgov-nct02666664-2020-05-11`, retrieved 2026-10-31)
- Primary completion: 2018-02-21 (actual) (ClinicalTrials.gov record NCT02666664, source copy `cardio:ctgov-nct02666664-2020-05-11`, retrieved 2026-10-31)
- Completion: 2018-03-28 (actual) (ClinicalTrials.gov record NCT02666664, source copy `cardio:ctgov-nct02666664-2020-05-11`, retrieved 2026-10-31)
- Results first posted: 2020-04-20 (ClinicalTrials.gov record NCT02666664, source copy `cardio:ctgov-nct02666664-2020-05-11`, retrieved 2026-10-31)
- Countries: United States; Canada; Germany; Netherlands; Poland; United Kingdom (ClinicalTrials.gov record NCT02666664, source copy `cardio:ctgov-nct02666664-2020-05-11`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02666664-2020-05-11`, retrieved 2026-10-31)

## The registry's words

- Brief title: Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)
- Condition: Hypercholesterolemia
- Condition: Atherosclerotic Cardiovascular Diseases
- Intervention (Drug): ETC-1002
- Intervention (Drug): Placebo
- Lead sponsor: Esperion Therapeutics, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: Esperion Therapeutics, Inc. (`cardio:org-esperion-therapeutics-inc`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol (`cardio:pubmed-30865796`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial (`cardio:pubmed-36813656`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: e2620acbca2c57f8adc998bb3060e0672654254aee79e48f83bc6ba2ca556cad
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
